Spruce biosciences provides clinical program updates and outlook for 2024

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for advancing tildacerfont for the treatment of adult and pediatric classic congenital adrenal hyperplasia (cah). “2023 was a year of exceptional clinica.
SPRB Ratings Summary
SPRB Quant Ranking